FRINDOVYX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FRINDOVYX (FRINDOVYX).
Frindovyx is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the synaptic cleft.
| Metabolism | Primarily metabolized by CYP2D6 and CYP3A4 to its active metabolite, norfrindovyx; also undergoes glucuronidation. |
| Excretion | Renal excretion of unchanged drug accounts for approximately 60% of the administered dose, with an additional 30% recovered as inactive metabolites in urine. Fecal/biliary elimination constitutes the remaining 10%. |
| Half-life | Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 24-30 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 48 hours in severe impairment (CrCl <30 mL/min). |
| Protein binding | 97% bound to serum albumin; minor binding to alpha-1-acid glycoprotein (<5%). |
| Volume of Distribution | 0.15-0.20 L/kg, indicating primarily intravascular distribution with limited extravascular penetration. |
| Bioavailability | Oral: 75-85% in the fasted state; reduced to 55-65% with high-fat meals. |
| Onset of Action | Intravenous: 2-5 minutes; oral: 30-45 minutes on an empty stomach. |
| Duration of Action | Intravenous: 4-6 hours; oral: 6-8 hours for the analgesic effect, with dose-dependent prolongation up to 12 hours at maximum recommended doses. |
10 mg orally once daily.
| Dosage form | SOLUTION |
| Renal impairment | eGFR 30-59 mL/min: 5 mg once daily. eGFR <30 mL/min: Not recommended. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: 5 mg once daily. Child-Pugh C: Not recommended. |
| Pediatric use | Not established for patients <18 years. |
| Geriatric use | No specific adjustment required based on age alone; monitor renal function and adjust per renal guidelines. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for FRINDOVYX (FRINDOVYX).
| Breastfeeding | Contraindicated during breastfeeding; M/P ratio 2.4, drug accumulates in breastmilk and may cause neonatal hypotension and hypoglycemia. |
| Teratogenic Risk | First trimester: Associated with major congenital malformations including neural tube defects and cardiovascular anomalies (incidence 5-8%). Second trimester: Increases risk of intrauterine growth restriction and preterm labor. Third trimester: May cause fetal tachycardia and metabolic acidosis at delivery. |
| Fetal Monitoring |
■ FDA Black Box Warning
Suicidality and Antidepressant Drugs: Frindovyx increases the risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders. Monitor closely for clinical worsening, suicidality, or unusual changes in behavior.
| Serious Effects |
Concomitant use with MAOIs, pimozide, or within 14 days of MAOI discontinuation; hypersensitivity to frindovyx or any excipients.
| Precautions | Serotonin syndrome, elevated risk of bleeding, activation of mania/hypomania, hyponatremia, angle-closure glaucoma, sexual dysfunction, QT prolongation at high doses. |
Loading safety data…
| Monthly fetal ultrasound for growth and anatomy; nonstress test or biophysical profile weekly after 32 weeks; maternal blood pressure and urine protein every clinic visit. |
| Fertility Effects | Reversible impaired spermatogenesis in males (reduced sperm count and motility); females may experience anovulatory cycles due to hypothalamic-pituitary suppression; effects resolve 3-6 months after discontinuation. |